Erschienen in:
01.06.2012 | Editorial
New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
verfasst von:
Eric Raymond, Philippe Ruszniewski
Erschienen in:
Targeted Oncology
|
Ausgabe 2/2012
Einloggen, um Zugang zu erhalten
Excerpt
Neuroendocrine tumor has long been considered as a rare tumor, although its prevalence makes it one of the most frequent gastrointestinal malignancies [
1]. In the eighties, streptozotocin-based chemotherapy allowed substantial improvements in the management of advanced pancreatic neuroendocrine tumors (PNETs) [
2,
3]. Subsequently, somatostatin analogues were shown to be useful for the control of symptomatic PNETs and also able to delay tumor progression in slow-growing midgut carcinoids [
4]. …